Search

Displaying results 121 - 130 of 6970 in total
  1. Drug

    Isavuconazole

    go.drugbank.com/drugs/DB11633
    ApprovedInvestigational

    It is proposed that the intravenous and oral dosing can be used interchangeably [L1482], without the need for a repeat loading dose when transitioning from an IV to an oral formulation [A32026]. … has a potential for nephrotoxicity [A32029].

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseProducts: CRESEMBA (POWDER FOR SOLUTION FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 MG/VIAL)
  2. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    candidates for cytotoxic chemotherapy [A98]. … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [L941].

    Products: MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL
  3. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl

    Products: POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG, POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30MG
  4. Drug

    Tolfenamic acid

    go.drugbank.com/drugs/DB09216
    Approved

    By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … It is used in the UK as a treatment for migraine under the name of Clotam.[L1292] In the US, it presents a Status class I by the FDA.

    Products: TOLFEDINE 4% W/V SOLUTION FOR INJECTION FOR DOGS AND CATS, Tolfine Solution for Injection 4.0% W/V
  5. Drug

    Peginterferon alfa-2b

    go.drugbank.com/drugs/DB00022
    ApprovedInvestigational

    -2b for the treatment of Hepatitis C [A19593]. … When combined together, Peginterferon alfa-2b and [Ribavirin] have been shown to achieve a SVR between 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment.

    Categories: Treatments for Hepatitis CProducts: PEG-INTRON CLEARCLICK FOR INJECTION 80 mcg/0.5 ml, PEG-INTRON CLEARCLICK FOR INJECTION 100 mcg/0.5 ml
  6. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma [L37674]. … Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts.

    Products: SOLUTION FOR INFUSION 20MG/ML, Folotyn 20mg/ml Solution for Infusion
  7. Drug

    Ivermectin

    go.drugbank.com/drugs/DB00602
    ApprovedInvestigationalVet approved

    [A238929] Until high-quality, peer-reviewed data regarding both the safety and efficacy of ivermectin for COVID-19 in humans becomes available, the use of ivermectin for these purposes should be avoided … With the advent of 2020 and the COVID-19 pandemic, ivermectin began garnering notoriety due to its off-label use for the prophylaxis and treatment of COVID-19.

    Mixtures: Eqvalan Duo Oral Paste for Horse, Heartgard Plus Chewable Tablet for Dogs - 26 - 50 lbsProducts: ECOMECTIN 6 MG/ G PREMIX FOR MEDICATED FEEDING STUFF FOR PIGS -Granules, Ivomec Premix for Pigs 0.6% w/w
  8. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    /CD3 bispecific monoclonal antibody approved for DLBCL. … [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies -

    Products: COLUMVI 1mg/mL Concentrate for Solution for Infusion
  9. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    [L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria

    Products: Soliris Concentrate for Solution for Infusion 300mg/vial, Soliris 10mg/ml Concentrate for Solution for Infusion
  10. Drug

    Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10584
    ApprovedInvestigational

    Mixtures: , Suspension for Injection, ADACEL SUSPENSION FOR INJECTIONCategories: Antiinfectives for Systemic Use